Could a common diabetes drug protect transplanted kidneys?
NCT ID NCT04965935
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether dapagliflozin, a drug used for type 2 diabetes, can lower blood pressure in people who have received a kidney transplant. Fifty-two participants took either the drug or a placebo for 12 weeks. The goal was to see if the drug helps control blood pressure and blood sugar, which are important for keeping the transplanted kidney healthy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Dapagliflozin (a diabetes drug that helps lower blood sugar and blood pressure)
What this could lead to
If successful, this could point toward a new way to manage blood pressure and diabetes in kidney transplant recipients, potentially improving long-term outcomes.
What could go wrong
This is a small, early-phase trial with only 52 participants, so results may not apply to everyone. The drug also carries risks like dehydration or infections in this vulnerable population.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Renal Physiology Laboratory
Toronto, Ontario, Canada